Diurnal Group plc announced that Alkindi (hydrocortisone granules in capsules for opening) has been approved by Swissmedic, the national authorisation and supervisory authority for drugs and medical products in Switzerland, as a replacement therapy of adrenal insufficiency (AI) for infants, children and adolescents (from birth to <18 years old). The Marketing Authorisation Application (MAA) was submitted by the Company's marketing and distribution partner in Switzerland, EffRx Pharmaceuticals (EffRx), in October 2020; EffRx continues to expect market launch of Alkindi in Switzerland during first half 2022. The MAA approval of Alkindi? in Switzerland is based on the European regulatory dossier and previously published clinical trial data.There are approximately 200 patients in Switzerland suffering from paediatric AI, providing an estimated total market opportunity for Alkindi? of approximately $1 million per annum. As previously announced, under the terms of the agreement, EffRx has the exclusive rights to market Alkindi? in Switzerland. In line with the Company's other distribution agreements, EffRx will be provided Alkindi? for sale from Diurnal's established European supply chain.